Linaclotide: A novel compound for the treatment of irritable bowel syndrome with constipation

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 15, 2013, Pages 2125-2132

  Rothstein, Robin D ^a   Friedenberg, Frank K ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Constipation; Guanylate cyclase C; Irritable bowel syndrome; Linaclotide

Indexed keywords

A 3309; BISACODYL; DEXTRIN; DOCUSATE CALCIUM; DOCUSATE SODIUM; GLYCEROL; ISPAGULA; LACTULOSE; LINACLOTIDE; LUBIPROSTONE; MACROGOL; MAGNESIUM CITRATE; MAGNESIUM SULFATE; METHYLCELLULOSE; PLACEBO; POLYCARBOPHIL; PRUCALOPRIDE; SORBITOL; UNCLASSIFIED DRUG;

ABDOMINAL CRAMP; BLOATING; CONSTIPATION; DIARRHEA; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FLATULENCE; GOVERNMENT REGULATION; HUMAN; HYPERVOLEMIA; IRRITABLE COLON; KIDNEY FAILURE; MELANOSIS; NAUSEA; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; SENNA; STOMACH IRRITATION; TREATMENT INDICATION; TREATMENT OUTCOME;

ANIMALS; CONSTIPATION; GASTROINTESTINAL AGENTS; HUMANS; IRRITABLE BOWEL SYNDROME; PEPTIDES; TREATMENT OUTCOME;

EID: 84884543562     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.833605     Document Type: Review

References (39)

1. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnouncements? ucm317505.htm [Last accessed 30 Augest 2012]
2. Higgins PD, Johanson JF. Epidemiology of constipation in North America: a systematic review. Am J Gastroenterol 2004;99:750-9
3. Drossman DA, Li Z, Andruzzi E, et al. US householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci 1993;38:1569-80
4. Longstreth G, Thompson W, Chey W, et al. Functional bowel disorders. Rome Criteria. Gastroenterology 2006;130:1480-91
5. Lovell RM, Ford AC. Global prevalence of, and risk factors for, irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 2012;10:712-21
6. Shih YC, Barghout VE, Sandler RS, et al. Resource utilization associated with irritable bowel syndrome in the United States 1987-1997. Dig Dis Sci 2002;47:1705-15
7. Lacy BE, Levenick JM, Crowell M. Chronic constipation: new diagnostic and treatment approaches. Therap Adv Gastroenterol 2012;5:233-47
8. Norimatsu Y, Moran AR, MacDonald KD. Lubiprostone activates CFTR, but not ClC-2. via the prostaglandin receptor (EP(4)). Biochem Biophys Res Commun 2012;426:374-9
9. Chey WD, Drossman DA, Johanson JF, et al. Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2012;35:587-99
10. Available from: http://www. synergypharma.com/pipeline/plecanatide
11. Miner PB, Surowitz R, Fogel R, et al. Plecanatide, a Novel Guanylate-Cyclase C (GC-C) Receptor Agonist, is Efficacious and Safe in Patients with Chronic Idiopathic Constipation (CIC): Results from a 951 Patient, 12 Week, Multi-Center Trial. Presented at DDW; Orlando, Fl; 2013
12. Available from: http://finance.yahoo.com/news/sk-biopharmaceuticals- drugprogram-granted-170800386.html
13. A phase 2 study to evaluate Pharmacodynamics of YKP10811 in patients with chronic or functional constipation. Sponsored by SK Life Science, ClinicalTrials. NCT01523184
14. Camilleri M, Van Outryve MJ, Beyens G, et al. Clinical trial: the efficacy of open-label prucalopride treatment in patients with chronic constipation-follow-up of patients from the pivotal studies. Aliment Pharmacol Ther 2010;32:1113-23
15. Simren M, Bajor A, Gillberg PG, et al. Randomised clinical trial: The ileal bile acid transporter inhibitor A3309 vs. placebo in patients with chronic idiopathic constipation-a double-blind study. Aliment Pharmacol Ther 2011;34:41-50
16. Chey WD, Camilleri M, Chang L, et al. A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation. Am J Gastro 2011;106:1803-12
17. Stable Solid Formulation of A GC-C Receptor Agonist Polypeptide Suitable for Oral Administration. US20100048489A1; 2010
18. Busby RW, Kessler MM, Bartolini WP, et al. Pharmacologic properties, metabolism, and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation. J Pharmacol Exp Ther 2013;344:196-206
19. Lucas KA, Pitari GM, Kazerounian S, et al. Guanylyl cyclases and signaling by cyclic GMP. Pharmacol. Rev 2000;52:375-414
20. Busby RW, Bryant AP, Bartolini WP, et al. Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit. Eur J Pharmacol 2010;649:328-35
21. Bryant AP, Busby RW, Bartolini WP, et al. Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract. Life Sci 2010;86:760-5
22. Eutamene H, Bradesi S, Larauche M, et al. Guanylate cyclase C-mediated antinociceptive effects of linaclotide in rodent models of visceral pain. Neurogastroenterol Motil 2010;312:1365-2982
23. Andresen V, Camilleri M, Busciglio IA, et al. Effect of 5 days linaclotide on transit and bowel function in females with constipation- predominant irritable bowel syndrome. Gastroenterology 2007;133:761-8
24. Linzess (linaclotide) capsules, prescribing information. Cambridge, Mass.: ironwood Pharmaceuticals. Available from: www.frx.com/pi/linzess-pi.pdf [Last accessed August 2012]
25. Bryant AP, Busby RW, Cordero EA, et al. The characterization of an active metabolite of MD-1100, a therapeutic agent in development for the treatment of IBS-C and chronic constipation. Gastroenterology 2006;130:T2034
26. Bryant AP, Busby RW, Cordero EA, et al. Md-1100, a therapeutic agent in development for the treatment of IBS-C, enhances intestinal secretion and transit, decreases visceral pain and is minimally absorbed in rats. Gastroenterology 2005;128:A464-4
27. Available from: http://www. druginformation.com/RxDrugs/L/ Linaclotide%20Capsules.html
28. Currie MG, Kurtz CB, Mahajan-Miklos S, et al. Effects of a single dose administration of MD-1100 on safety, tolerability, exposure, and stool consistency in healthy subjects. Am J Gastoenterology 2005;100:S328
29. Kurtz CB, Fitch D, Busby RW. Effects of multidose administration of MD-1100 on safety, tolerability, exposure, and pharmacodynamics in healthy subjects. Gastroenterology 2006;130(Suppl 2):A26
30. Johnston JM, Kurtz CB, Drossman DA, et al. Pilot Study on the Effect of Linaclotide in Patients With Chronic Constipation. Am J Gastroenterol 2009;104:125-32
31. Lembo AJ, Kurtz CB, Macdougall JE, et al. Efficacy of linaclotide for patients with chronic constipation. Gastroenterology 2010;138:886-95
32. Johnston JM, Kurtz CB, MacDougall JE. Linaclotide Improves Abdominal Pain and Bowel Habits in a Phase IIb Study of Patients With Irritable Bowel Syndrome With Constipation. Gastroenterology 2010;139:1877-86
33. Lembo AJ, Schneier HA, Shiff SJ, et al. Two randomized trials of linaclotide for chronic constipation. N Engl J Med 2011;365:527-36
34. Rao S, Lembo AJ, Shiff SJ, et al. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol 2012;107:1714-24
35. Chey WD, Lembo AJ, Lavins BJ, et al. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Dig Dis Sci 2013;58:509-18
36. Quigley EM, Tack J, Chey WD, et al. Randomised clinical trials: linaclotide phase 3 studies in IBS-C-a prespecified further analysis based on European Medicines Agency-specified endpoints. Aliment Pharmacol Ther 2013;37:49-61
37. Available from: http://www.accessdata. fda.gov/drugsatfda-docs/nda/2012/ 202811Orig1s000CrossR.pdf
38. Red Book Online. Ann Arbor, Mich.: truven Health Analytics; Linaclotide. Available from: www.truvenhealth.com [Last accessed 11 July 2013]
39. Red Book Online. Ann Arbor, Mich.: truven Health Analytics; Lubiprostone. Available from: www.truvenhealth.com [Last accessed 11 July 2013]